Abstract : This study evaluated the urinary metabolism of ursodeoxycholic acid UDCA by measuring 7 -N-acetylglucosaminide and 3 -sulfate composition in neonates to adolescents using liquid chromatography electrospray ionization tandem mass spectrometry LC/ESI-MS/MS . We obtained urine from 13 babies, corrected gestational age CGA 37-70 weeks, receiving UDCA to treat cholestasis due to total parenteral nutrition TPN and 8 patients, aged from 9 months to 15 years, who were treated with oral UDCA administration. The ratios of each UDCA conjugate to total UDCA were as follows : at CGA 37-42 weeks : nonamidated and glycine-or taurine-amidated ursodeoxycholic acid UDCAs : 44.0 8.0% mean SD , UDCAs 3 -sulfate UDCAs-3S : 37.8 10.1%, UDCAs 7 -N-acetylglucosaminide UDCAs-7NAG : 18.1 14.9% ; at 9 months-3years : UDCAs : 15.7 23.2%, UDCAs-3S : 37.2 8.8%, UDCAs-7NAG : 47.0 22.1%. The ratios of UDCAs-3S and UDCAs-7NAG increased gradually between the ages of 5 and 15 years, as follows : UDCAs, 2.2 1.3% ; UDCAs-3S, 51.2 22.9% ; and, UDCAs-7NAG, 46.6 22.6%. The ratio of 3-sulfooxy-7-N-acetylglucosaminylUDCAs UDCAs-3S-7NAG lowered by 0.2% per each age group. Urinary UDCAs-7NAG was not detectable in 2 of 21 patients, who were thus considered to have 7 -hydroxy bile acid N-acetylglucosaminyl transferase UGT3A1 deficiency. The enzyme activity of N-acetylglucosaminyl transferase to UDCAs was at the same degree as sulfotransferase to UDCAs in early neonates, but reached the adult values by 3-5 years.
lic acid CDCA , are conjugated predominantly with taurine or glycine amino acids at the position-24 carboxylic group of BAs. After secretion into the small intestine through the bile duct, secondary BAs, deoxycholic acid DCA , lithocholic acid LCA , and UDCA, are converted from the primary BAs by the action of intestinal microbiota. Most primary and secondary BAs are reabsorbed back to the liver via the portal circulation for re-secretion into bile via a process called enterohepatic circulation 1 .
BAs consist of free BAs and their conjugated forms, with two amino acids glycine and taurine , sulfonic acid, glucoside, glucuronic acid, and N-acetylglucosamine [2] [3] [4] [5] . The compositions of these BAs and their conjugated forms can differ signi cantly at different periods of life from neonates to adults and also between healthy humans and patients with disorders such as liver disease.
In patients with severe cholestasis for example, BAs are excreted into the urine. In patients with severe cholestasis for example, BAs are more likely excreted into the urine as the sulfate conjugation forms mostly at C-3 and increases BA hydrophilicity [6] [7] [8] . With lower amounts, BAs are also glucuronidated at C-3 or C24. N-acetylglucosaminidation is seemingly an even more selective glycosidic conjugation reaction because only 7 -hydroxylated BAs seem to be conjugated with N-acetylglucosamine in adult patients treated with UDCA 9, 10 , and the 7 -N-acetylglucosaminyl-UDCA glycine conjugate GUDCA-7NAG is part of the main pathway for excretion into urine together with 3 -sulfooxy-UDCA UDCA-3S glycine conjugates in adults. The safe and ef cient drug metabolism and excretion systems are established through neonatal, infant, child, and adolescent periods 11 . During infancy, these changes are dynamic and largely related to organ functions important in metabolism, excretion, and changes in body composition ; however, because changes in UDCA metabolism and the resultant metabolites are not known during infancy, we aimed to evaluate the UDCA metabolites, UDCAs-7NAG and UDCAs-3S, in urine.
Reported methods for UDCAs-7NAG analysis in the urine of primary biliary cirrhosis PBC adult patients with UDCA treatment include fast atom bombardment mass spectrometry FAB-MS 12 , high performance liquid chromatography HPLC 10 , and enzyme-linked immunosorbent assay ELI-SA 13 . In contrast, LC/ESI-MS/MS has been used for the analysis of UDCAs-3S 14, 15 , but not for UDCAs-7NAG analysis. This study sought to establish a highly sensitive measurement of urinary UDCAs-7NAG using LC/ESI-MS/MS, including its application to clinical samples, especially in low birth weight LBW neonates requiring the administration of UDCA for cholestasis induced by total parenteral nutrition TPN . Using this method, we found that neonates mainly excrete glycoursodeoxycholic acid GUDCA and tauroursodeoxycholic acid TUDCA and considerable amounts of both UDCAs-3S and UDCAs-7NAG. The urinary UDCAs-3S and UDCAs-7NAG levels gradually increased with age, and the urinary levels of 3 to 5 year olds were close to that of adolescents being administered exogenous UDCA.
Materials and methods

Chemicals and reagents
Authentic reference bile acids used in this study were purchased from Sigma-Aldrich St. Louis, MO, USA as follows : CA, CDCA, UDCA, DCA, LCA, and d 4 -CA as an internal reference standard for LC/ESI-MS/MS analysis . Glycine-and taurine-conjugated bile acids were also purchased from Sigma-Aldrich. Other internal reference standards were also used, namely d 4 16 , as were the glycine-and taurine-conjugates, 7 -hydroxy-3-oxo-4-cholenoic acid and 7 ,
12 -dihydroxy-3-oxo-4-cholenoic acid 17 , and 5-cholenoic acids 3-sulfates, 3 -hydroxy-5-cholenoic acid, 3 ,7 -dihydroxy-5-cholenoic acid, and 3 ,7 ,12 -trihydroxy-5-cholenoic acid 18, 19 . In addition, we synthesized 7 -N-acetylglucosaminyl-UDCA UDCA-7NAG , GUDCA-7NAG, 7 -N-acetylglucosaminyl-UDCA N-2-sulfoethyl amide TUDCA-7NAG , 3 -sulfooxy-7 -N-acetylglucosaminyl-UDCA UDCA-3S-7NAG , 3 -sulfooxy-7 -N-acetylglucosaminyl-UDCA Ncarboxymethyl amide GUDCA-3S-7NAG , and 3 -sulfooxy-7 -N-acetylglucosaminyl-UDCA N-2-sulfoethyl amide TUDCA-3S-7NAG 20, 21 . Chemical structures of the unconjugated and conjugated ursodeoxycholic acids measured in this study are shown in Fig. 1 . All solvents and reagents used were analytical reagent grade and purchased from Kanto Chemical Co., Inc. Tokyo, Japan . An InertSep C18-B 100 mg/1 ml solid phase extraction cartridge was obtained from GL Sciences Inc. Tokyo, Japan . 
Preparation of standard solutions
The individual stock solutions of bile acids were prepared separately at 5 µmol / ml in ethanol and the stock solutions were stored at 20ºC. The individual stock solutions were mixed equally for analysis of unknown samples and ve point-calibration standard solutions 30, 100, 300, 1,000, 3,000 pmol / ml for LC/ESI-MS/MS analysis were prepared in 20% acetonitrile. The calibration standard solutions were stable in analytical glass tubes for at least 2 weeks at 4ºC.
Clinical samples
Randomly collected urine samples were obtained from low birth weight LBW and normal birth weight NBW controls UDCA non-administration and patients who required UDCA for treatment of TPN-induced cholestasis. The age is shown as corrected gestational age CGA , which is the gestational age plus the weeks after birth. In total, we analyzed samples from 8 controls of 36-44 weeks CGA LBW ; 3 ; 1,198-1,857 g, NBW ; 5 , 4 patients of 37-42 weeks CGA LBW ; 2 ; 995-1,379 g, NBW ; 2 , 5 patients of 44-49 weeks CGA LBW ; 4 ; 764-1,980 g, NBW ; 1 , 4 patients of 55-70 weeks CGA LBW ; 4 ; 869-1,637 g , 4 patients aged from 9 months to 3 years, and 4 patients aged 5-15 years. All the urine specimens were stored at 20ºC until use. The analysis values were standardized to creatinine excretion, being expressed as mmol / mol creatinine mmol / molCr in each specimen. The urinary creatinine levels were determined using the Jaffe method 22 .
Urine samples investigated in this study were collected through the patients attending physicians who asked Junshin Clinic Bile Acid Institute for bile acid analysis. Upon collection of the samples, the physicians obtained permissions from the patients in accordance with the code of ethics of their medical institution.
Sample preparation
A 10 µl volume of deuterium-labeled internal standard,
4 -GCDCA, and d 4 -TCDCA were mixed equally, and then added at 100 nmol / ml each in 50% ethanol to 100 µl of sample. The solution was transferred onto the solid-phase extraction cartridge InertSep C18-B 100mg/1ml, pre-conditioned with 1 ml of methanol and 3 ml of H 2 O , which was washed with 1 ml of H 2 O and then eluted with 1 ml of 90% ethanol. After evaporation of the solvent, the residue was dissolved in 1 ml of 20% acetonitrile, and then 20 µl of the solution was injected into the LC/ESI-MS/MS.
LC/ESI-MS/MS analysis
The LC/ESI-MS/MS system comprised a TSQ Quantum Discovery Max mass spectrometer Thermo Fisher Scientific, San Jose, CA, USA equipped with an ESI probe and Surveyor HPLC system Thermo Fisher Scienti c . A chromatography separation column, InertSustain C18 150 mm 2.1 mm ID, 3 µm particle size ; GL Sciences Inc., Tokyo, Japan , was employed at 35 C. A mixture of 10 mM ammonium acetate and acetonitrile was used as the eluent, and the separation carried out by linear gradient elution at a ow rate of 0.2 ml / min. To operate the LC/ESI-MS/MS, the spray voltage and vaporizer temperature were set at 3,500 V and 330 C, respectively. The sheath and auxiliary gas nitrogen pressures were set at 50 and 10 arbitrary units, respectively, and the ion transfer capillary temperature was 330 C. The collision gas argon pressure and the collision energy were kept at 1.3 mm Torr and 27-55 eV, respectively, all in the negative ion mode 19, 23 .
Method validation
The method was fully validated, according to the ICH Q2 R1 24 . Method linearity was determined by analyzing ve-point calibration standard solutions. Accuracy and precision were assessed using the three concentrations of urine samples spiked with a known amount of bile acids, evaluated by analyzing ve replicates per run of samples contained in one run per day over a 5-day period. LOD limit of detection was established using a method based on the calibration curves, LOD 3.3 /S the standard deviation of the response, S the slope of the calibration curve used as deviation of y-intercept . Matrix effects were determined by comparing the linearity of working solutions prepared from extracted human urine samples to linearity in 20% acetonitrile.
Results
LC/ESI-MS/MS analysis of unconjugated and conjugated UDCA
Using ESI-MS operating in the negative-ion mode, the related UDCA compounds analyzed herein possess a sulfooxy group at the 3 position, and a carboxyl group or amides conjugated with glycine or taurine at the 24 position, terminal carbon atom of the side chain. LC/ESI-MS/ MS analysis of UDCAs, UDCAs-3S, UDCAs-7NAG, and UDCAs-3S-7NAG were easily ionized by the electron spray ionization and fragmented under the condition of low-energy collision-induced dissociation CID . The compounds precursor ions mainly formed from the deprotonated molecule M H or half of the 3-sulfate compounds formed doubly charged molecules M 2H 2 .
Those product ions were optimized at m/z 74 for glycine-conjugated bile acids, at m/z 124 for taurine-conjugate bile acids, and at m/z 97 for 3 variants of UDCAs-3S such as bile acid sulfates 19, 23 . Whereas UDCAs-7NAG provided UDCA at m/z 391.3, GUDCA-7NAG produced NAG H 2 O at m/z 202.1, TUDCA-7NAG gave M NAG at m/z 480.5, and GUDCA-3S-7NAG gave M SO 3 at m/z 651.6 Table 1 . Typical selected reaction monitoring SRM chromatograms for the authentic 12 variants of UDCA and related compounds, as shown in Fig. 2 , required 60 min for the simultaneous separation and determination of all bile acids.
Linearity, sensitivity, and precision
The linearity of the method was entered by 10 variants of conjugated UDCA standard curve calibrators ranging from 30 to 3,000 pmol / ml. For the other acids, UDCA and GUDCA-7NAG, standard linearity ranged from 100 to 3,000 pmol / ml. Peak area ratios analytes / internal standard were proportional to the concentration. The calibration curves appeared linear and the slopes, the intercepts, and the correlation coef cients were determined by least square lines with a weighting factor of 1 / concentration 2 . The correlation coef cients and detection limit LOD 3.3 / S the standard deviation of the response, S the slope of the calibration curve Table 2 .
To con rm the precision of UDCA-related quanti cation using LC/ESI-MS/MS, 5 replicates per run of samples and 1 run per day over a 5-day period were analyzed. Precision of compounds, measured as C.V. % , ranged from 0.6% to 12.9% and from 3.3% to 25.9% for intra-day and inter-day measurements, respectively Table 3 .
Spiked urine samples were derived by adding individual derivative reagents to prepare the solution for recovery test. Five replicates at low and medium quality concentrations for 12 variants of UDCA-related bile acids were determined. Absolute recovery was determined to evaluate the measurement accuracy of the derivatives added to three male urine samples in known quantities. Recoveries of UDCA-related bile acids from all urine samples are listed in Table 4 . The results show no signi cant ion suppression or enhancement effects, nor were there signi cant matrix effects for other BAs.
Application
We analyzed 60 variant bile acids, usual bile acids non-amidated and amidated with glycine or taurine at their carboxylic group, with further conjugation to sulfonic acid at the 3 position, in addition 3 -hydroxy- 5 -bile acids unconjugated and conjugated with those and 3-oxo- 4 -bile acids nonamidated and amidated with glycine or taurine at their carboxylic group. UDCAs-7NAG and UDCAs-3S-7NAG were newly determined in this study. Fig. 3 shows the level of 60 variant BAs in 8 control samples, 13 urine samples obtained from patients including LBW and NBW being administered UDCA for TPN-related cholestasis from CGAs of 37 to 70 weeks and 8 urine samples obtained from UDCA administration patients aged from 9 months to 15 years. The ratio of total UDCA to total BAs TBA in the control urines n 8 from CGA 36-44 weeks was lower, 0.7%, whereas this ratio in urine from patients of CGA 37-42 weeks ranged from 26.5 to 89.9%. Fig. 4 compares UDCA-related BA composition in urine from individuals aged CGA 37-70 weeks to those aged 9 months to 15 years in patients treated with UDCA. The ratio to total UDCA at CGA 37-42 weeks were as follows ; UDCAs : 44.0 8.0%, UDCAs-3S : 37.8 10.1%, UDCAs-7NAG : 18.1 14.9%. And the ratio to total UDCA at 9 months-3years were ; UDCAs : 15.7 23.2%, UDCAs-3S : 37.2 8.8%, and UDCAs-7NAG : 47.0 22.1%. Followed by UDCAs, the ratios of UDCAs conjugates by N-acethylglucosamine and sulfonic acid were close to adolescent UDCA components at 3 years. Of the 21 patients treated with UDCA, 2 did not excrete UDCAs-7NAG, which may be considered as UDP-glycosyltransferase UGT3A1 deficiency. UDCAs-3S-7NAG components were detected at levels lower than 0.2% for all ages. 
Discussion
We describe here a simple, sensitive, and accurate LC/ESI-MS/MS method for the determination of UDCA-7NAG, GUDCA-7NAG, TUDCA-7NAG, and their 3 -sulfonic acid double conjugates in urine. This method also analyzed other 54 BA variants, such as usual BAs, 3-oxo-4 -BAs, 3 -hydroxy- 5 -BAs, and those simultaneously conjugated to glycine, taurine, and sulfonic acid 19, 23 . We found that the MS/MS conditions of measurement for UDCAs-7NAG 25, 26 .
While large amounts of UDCAs-7NAG in the urine and serum of PBC patients treated with UDCA indicates disease progression 9 , the physiological signi cance of BA N-acetylglucosaminide is not clear, although it might be a metabolite of conversion into a form capable of urinary excretion or of sulfated BA formation. HPLC methods have been used to analyze UDCAs-7NAG concentrations in adult urine and serum, including uorescence-labeled treatment, GC / MS method using trimethylsilylether derivatization, and immunoassay using diluted sample specimen, but not LC/ESI-MS/MS. Further, the levels of UDCAs-7NAG in neonates or infants have not been analyzed by any method. BA N-acetylglucosamination might be considered to occur as UGT3A1, mainly in the kidney, while sulfation activity is present in both the liver and kidney, and the activity is increased relatively early in the neonatal period. These results describe the transition of UDCA-7 -N-acetylglucosaminide and 3 -sulfate urine concentrations from neonates including LBW to adolescents receiving UDCA using LC/ESI-MS/MS analysis. General enzymes involved in drug metabolism are those of the cytochrome P450 CYP family phase reactions and the uridine diphosphate glucuronosyltransferase UGT , sulfotransferase, glutathione-S-transferase, and N-acetyltransferase families phase reactions . There are also specific isozymes within each family that mature at different rates during the rst several years of life. The effect on metabolism of a specific medication thus depends on the dominant enzymatic pathways responsible for metabolism of the drug 27, 28 . Herein, we compared the level of sulfate conjugation at C-3 -OH and N-acetylglucosaminidation at C-7 -OH to UDCA to metabolites of UDCA in neonatal urine from patients treated with UDCA, and found that there are activities of both N-acetylglucosaminidation to UDCA and sulfate conjugation, already existing in the early neonatal period CGA 37-42w . This expression gradually increases in the rst 1-2 years after birth and stabilizes at 3-5 years. The urinary concentration ratios of GUDCA-3S and GUDCA-7NAG to total UDCA are about 45%, which could be related to the maturation of this pathway after UDCA administration in the neonate age groups compared to the adolescents group. Sulfate or glycine conjugation of general drug metabolism appears to be very ef cient at birth 27, 28 , while the maturation of sulfation to UDCA was not likely to be earlier than N-acethylglucosaminidation. The UGT3A1 de ciency is reported to be about 10% in the study of the Niemann Pick Type C biomarker analyzing 3 -sulfooxy-7 -N-acethylglucosaminyl-5 -cholen-24-oic acid 29 , and similarly in this study, 2 of 21 samples showed no UDCAs-7NAG.
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